Investment Thesis
MetaVia is a pre-commercial biotech with minimal revenue ($85K) experiencing severe operational losses ($4M+) and a deteriorating revenue decline (-44.6% YoY). At current cash burn rates of $4.3M quarterly, the company has only 3-4 quarters of runway remaining, indicating imminent financial distress without successful capital raises or product commercialization.
Strengths
- Working capital position of 2.73x current ratio provides near-term liquidity
- No long-term debt on balance sheet provides flexibility for future financing
- Cash position of $13.7M provides runway for operational expenses in near term
Risks
- Minimal revenue of $85K indicates no viable product commercialization or market traction
- Operating cash burn of $4.3M per period with limited runway of 3-4 quarters
- Revenue declining sharply at -44.6% YoY suggesting deteriorating business conditions or pilot phase failure
- Operating losses of $4M vastly exceed revenue, indicating business model is not viable
- Negative ROE of -42.1% and ROA of -26.6% destroying shareholder and asset value
- No insider Form 4 activity in 90 days suggests management lacks confidence in company trajectory
Key Metrics to Watch
- Monthly operating cash burn rate and cash runway remaining
- Revenue trends and new product commercialization milestones
- Operating expenses and cost reduction initiatives
- Capital raise announcements and cash position sustainability
Financial Metrics
Revenue
85.0K
Net Income
-3.8M
EPS (Diluted)
$-0.79
Free Cash Flow
-4.3M
Total Assets
14.4M
Cash
13.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,735.3%
Net Margin
-4,497.6%
ROE
-42.1%
ROA
-26.6%
FCF Margin
-5,011.8%
Balance Sheet & Liquidity
Current Ratio
2.73x
Quick Ratio
2.73x
Debt/Equity
0.00x
Debt/Assets
36.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:50:44.248794 |
Data as of: 2026-03-31 |
Powered by Claude AI